Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

Jordi M. Serra, Antonio Gutiérrez, Regina Alemany, María Navarro, Teresa Ros, Carlos Saus, Jordi Ginés, Antonia Sampol, Juan Carlos Amat, Lorenzo Serra-Moisés, Javier Martín, Antonio Galmés, Oliver Vögler and Joan Besalduch
Molecular Pharmacology June 2008, 73 (6) 1679-1687; DOI: https://doi.org/10.1124/mol.107.043372
Jordi M. Serra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Gutiérrez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Regina Alemany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
María Navarro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Ros
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Saus
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Ginés
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonia Sampol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Carlos Amat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Serra-Moisés
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Martín
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Galmés
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Vögler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan Besalduch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Non-small-cell lung cancer (NSCLC) is characterized by severe resistance to chemotherapy. Here, we demonstrate that A549 adenocarcinoma cells permanently differentiate with the antimetabolites methotrexate (MTX) and gemcitabine (GE) when blocking the resistance mechanism that normally counteracts this process. MTX (1-10 μM) and GE (1 μM) induced growth arrest accompanied by sustained extracellular signal-regulated kinase (ERK1/2) phosphorylation and moderate reduction of c-Myc levels after 96 h, whereas only a low percentage of the cells differentiated. Combination with the mitogen-activated protein kinase kinase (MEK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis-(methylthio)butadiene (U0126) reduced MTX- or GE-induced ERK1/2 over-phosphorylation, nearly abolished c-Myc expression, and provoked radical morphological changes in all cells. Besides the appearance of multilamellar bodies and intracellular cytokeratin reorganization, modulation of molecular markers occurred in a manner consistent with differentiation (gelsolin, +300%; surfactant protein A and C, -70%). Similar to U0126, c-Myc inactivation with specific small interfering RNA initiated differentiation only in the presence of MTX, demonstrating that inhibition of the mitogen-activated protein kinase/ERK pathway alone or down-regulation of c-Myc is not sufficient to induce this process. It is noteworthy that withdrawal of antitumoral drugs and U0126 neither reversed differentiation nor reactivated proliferation. Our results reveal that maintenance of a certain threshold of c-Myc expression through sustained ERK1/2 activation represents a molecular mechanism that confers resistance to antimetabolite-induced differentiation in A549 cells, and provide a novel molecular basis for therapeutic strategies based on irreversible differentiation of cancer cells using conventional chemotherapeutic antimetabolites in combination with inhibitors of the MEK/ERK pathway or c-Myc.

Footnotes

  • This work was supported by Grants “Nous estudis immunogenotipics en la classificació i tractament de la leucèmia mieloide aguda i síndrome mielodisplàsica”, ISCII number G03/008 and PROGECIB-8A (Conselleria d'Economia, Hisenda i Innovació, Govern Balear). The Dorothy and Jim Bird Foundation also provided funds for this study. R.A. and O.V. are supported by the Spanish I3 Programme (“Programa de Incentivación de la Incorporación e Intensificación de la Actividad Investigadora”).

  • J.M.S., A.G., and R.A. contributed equally to this work.

  • ABBREVIATIONS: NSCLC, non-small-cell lung cancer; MTX, methotrexate; GE, gemcitabine; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase kinase; U0126, 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene; siRNA, small interfering RNA; PARP, poly(ADP-ribose) polymerase; SP-A, surfactant protein A; SP-C, surfactant protein C; TS, thymidylate synthase.

    • Received November 9, 2007.
    • Accepted March 19, 2008.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 73 (6)
Molecular Pharmacology
Vol. 73, Issue 6
1 Jun 2008
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

Jordi M. Serra, Antonio Gutiérrez, Regina Alemany, María Navarro, Teresa Ros, Carlos Saus, Jordi Ginés, Antonia Sampol, Juan Carlos Amat, Lorenzo Serra-Moisés, Javier Martín, Antonio Galmés, Oliver Vögler and Joan Besalduch
Molecular Pharmacology June 1, 2008, 73 (6) 1679-1687; DOI: https://doi.org/10.1124/mol.107.043372

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

Jordi M. Serra, Antonio Gutiérrez, Regina Alemany, María Navarro, Teresa Ros, Carlos Saus, Jordi Ginés, Antonia Sampol, Juan Carlos Amat, Lorenzo Serra-Moisés, Javier Martín, Antonio Galmés, Oliver Vögler and Joan Besalduch
Molecular Pharmacology June 1, 2008, 73 (6) 1679-1687; DOI: https://doi.org/10.1124/mol.107.043372
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Polypharmacology of CBL0137 in the African Trypanosome
  • Peptide-mediated differential signaling at GPR83
  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics